PATIENT-RELATED FACTORS AND CLINICAL MANAGEMENT OUTCOMES OF RETINOBLASTOMA IN CALABAR, NIGERIA
Copyright © 2023 by West African Journal of Medicine..
Background: Retinoblastoma is curable in industrialized countries. However, it is associated with mortality in resource-poor nations due to disparities and poor access to eye care. Aim was to determine the relationships between patient-related factors and clinical outcomes of Retinoblastoma management in a tertiary hospital in Nigeria.
Materials and methods: This was a retrospective study of all children who were diagnosed and treated for Retinoblastoma from January 2017 through December 2022. Information obtained from their records included biosocioeconomic data, symptoms, lag time from initial symptoms, staging, treatment and outcome (dead or alive).
Results: Fifty-three patients, aged 6 to 88 months on first hospital presentation were recruited. There were 29(54.7%) females and 20(37.7%) patients died. Parental low socioeconomic class, rural residence and poor nutrition occurred more in those that survived, though not significantly (p>0.05). Median(interquartile) age at diagnosis [24(18-36) months, p=0.005] and lag time [13(6-20) months, p=0.274] were low in the survived group. Bilateral Retinoblastoma (20.8%,p=0.002), brain metastasis (22.6%,p<0.001), IRSS IV (18.9%,p=0.01) and relapse (34%,p<0.001) occurred more among the patients that died. The overall survival (OS) was 22(11.77-32.23) months with 1-year OS of 63%. Treatment with only chemotherapy [HR 4.76(95%CI:1.726-13.128)], incomplete chemotherapy [HR 5.61(95%CI:1.271-24.741)], relapse [HR 5.98(95%CI:1.376-25.983)] and eye surgery after 3 chemotherapy cycles [HR 8.22(95%CI:1.087-62.239)] were predictors of mortality.
Conclusion: Early presentation of retinoblastoma especially of advanced and bilateral disease may lead to improved survival if chemotherapy and eye surgery are appropriately performed. Routine screening and immediate referral of retinoblastoma particularly in rural areas are recommended.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
West African journal of medicine - 40(2023), 12 Suppl 1 vom: 04. Dez., Seite S36-S37 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nkanga, Elizabeth D [VerfasserIn] |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Revised 09.12.2023 published: Print Citation Status In-Process |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM365609854 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365609854 | ||
| 003 | DE-627 | ||
| 005 | 20231229123208.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365609854 | ||
| 035 | |a (NLM)38070170 | ||
| 035 | |a (PII)West Afr J Med. | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nkanga, Elizabeth D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PATIENT-RELATED FACTORS AND CLINICAL MANAGEMENT OUTCOMES OF RETINOBLASTOMA IN CALABAR, NIGERIA |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 09.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status In-Process | ||
| 520 | |a Copyright © 2023 by West African Journal of Medicine. | ||
| 520 | |a Background: Retinoblastoma is curable in industrialized countries. However, it is associated with mortality in resource-poor nations due to disparities and poor access to eye care. Aim was to determine the relationships between patient-related factors and clinical outcomes of Retinoblastoma management in a tertiary hospital in Nigeria | ||
| 520 | |a Materials and methods: This was a retrospective study of all children who were diagnosed and treated for Retinoblastoma from January 2017 through December 2022. Information obtained from their records included biosocioeconomic data, symptoms, lag time from initial symptoms, staging, treatment and outcome (dead or alive) | ||
| 520 | |a Results: Fifty-three patients, aged 6 to 88 months on first hospital presentation were recruited. There were 29(54.7%) females and 20(37.7%) patients died. Parental low socioeconomic class, rural residence and poor nutrition occurred more in those that survived, though not significantly (p>0.05). Median(interquartile) age at diagnosis [24(18-36) months, p=0.005] and lag time [13(6-20) months, p=0.274] were low in the survived group. Bilateral Retinoblastoma (20.8%,p=0.002), brain metastasis (22.6%,p<0.001), IRSS IV (18.9%,p=0.01) and relapse (34%,p<0.001) occurred more among the patients that died. The overall survival (OS) was 22(11.77-32.23) months with 1-year OS of 63%. Treatment with only chemotherapy [HR 4.76(95%CI:1.726-13.128)], incomplete chemotherapy [HR 5.61(95%CI:1.271-24.741)], relapse [HR 5.98(95%CI:1.376-25.983)] and eye surgery after 3 chemotherapy cycles [HR 8.22(95%CI:1.087-62.239)] were predictors of mortality | ||
| 520 | |a Conclusion: Early presentation of retinoblastoma especially of advanced and bilateral disease may lead to improved survival if chemotherapy and eye surgery are appropriately performed. Routine screening and immediate referral of retinoblastoma particularly in rural areas are recommended | ||
| 650 | 4 | |a Congress | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Clinical outcome | |
| 650 | 4 | |a Eye surgery | |
| 650 | 4 | |a Patient factors | |
| 650 | 4 | |a Retinoblastoma | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Nlemadim, Anthony C |e verfasserin |4 aut | |
| 700 | 1 | |a Arazi, Mattan |e verfasserin |4 aut | |
| 700 | 1 | |a Nkanga, Dennis G |e verfasserin |4 aut | |
| 700 | 1 | |a Duke, Roseline E |e verfasserin |4 aut | |
| 700 | 1 | |a Fabian, Ido D |e verfasserin |4 aut | |
| 700 | 1 | |a Nkanga, Essemfon D |e verfasserin |4 aut | |
| 700 | 1 | |a Odey, Friday A |e verfasserin |4 aut | |
| 700 | 1 | |a Meremikwu, Martin M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t West African journal of medicine |d 1993 |g 40(2023), 12 Suppl 1 vom: 04. Dez., Seite S36-S37 |w (DE-627)NLM012653942 |x 0189-160X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:12 Suppl 1 |g day:04 |g month:12 |g pages:S36-S37 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 12 Suppl 1 |b 04 |c 12 |h S36-S37 | ||